Topics

Dupilumab (Dupixent) for Asthma.

07:00 EST 15th February 2020 | BioPortfolio

Summary of "Dupilumab (Dupixent) for Asthma."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: American family physician
ISSN: 1532-0650
Pages: 244-245

Links

DeepDyve research library

PubMed Articles [1078 Associated PubMed Articles listed on BioPortfolio]

Dupilumab: Basic aspects and applications to allergic diseases.

Interleukin (IL)-4 and IL-13, signature type 2 cytokines, exert their actions by binding to two types of receptors sharing the IL-4R α chain (IL-4Rα). Since IL-4 and IL-13 play important and redunda...

Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma.

Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation, including immunoglobulin E (IgE)-mediated allergic inflammation in asthma. In t...

Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma With Self-reported Chronic Rhinosinusitis.

Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-13 signaling, key drivers of type 2 inflammation. In the phase 3 study (NCT02414854), a...

Use of dupilumab on the treatment of moderate-to-severe asthma: a systematic review.

The objective of this article was to conduct a systematic review of the treatment of moderate-to-severe asthma by administrating Dupilumab.

Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation.

Dupilumab, a fully human monoclonal antibody that binds IL-4Rα and inhibits signaling of both IL-4 and IL-13, has shown efficacy across multiple diseases with underlying type 2 signatures and is appr...

Clinical Trials [2158 Associated Clinical Trials listed on BioPortfolio]

Study of Adult Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

A long-term observational registry in patients with atopic dermatitis initiating treatment with DUPIXENT® (dupilumab)

Observational Study of Adult Patients Receiving Dupixent® for Atopic Dermatitis (AD)

Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease ...

Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)

Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study. ...

Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.

In asthmatics with airway hyperresponsiveness and a "T2 immune signature" (type 2), Dupilumab will suppress airway hyperresponsiveness (assessed by methacholine PC20 ≤ 4 mg/mL (PC20: pro...

BioDay Registry: Data Collection Regarding Dupixent in Patients With Atopic Dermatitis in Daily Practice

Atopic Dermatitis (AD) is the most common chronic inflammatory skin disease in the Netherlands with more than 400.000 patients suffering from this disease. For patients with difficult to t...

Medical and Biotech [MESH] Definitions

Asthma attacks caused, triggered, or exacerbated by OCCUPATIONAL EXPOSURE.

Asthma attacks following a period of exercise. Usually the induced attack is short-lived and regresses spontaneously. The magnitude of postexertional airway obstruction is strongly influenced by the environment in which exercise is performed (i.e. inhalation of cold air during physical exertion markedly augments the severity of the airway obstruction; conversely, warm humid air blunts or abolishes it).

Drugs that are used to treat asthma.

A beta-adrenergic agonist used in the treatment of asthma and bronchospasms.

Adrenergic beta-2 agonist used as bronchodilator for emphysema, bronchitis and asthma.

Quick Search
DeepDyve research library

Relevant Topic

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...


Searches Linking to this Article